Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Westpac Banking Corp

Westpac Banking Corp increased its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 24.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 41,173 shares of the medical equipment provider's stock after purchasing an additional 8,200 shares during the quarter. Westpac Banking Corp's holdings in Hologic were worth $2,968,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. General Partner Inc. bought a new position in Hologic in the 4th quarter valued at approximately $26,000. Venturi Wealth Management LLC lifted its holdings in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Finally, Smithfield Trust Co raised its position in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have commented on HOLX shares. Morgan Stanley decreased their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. William Blair reissued an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Stephens restated an "overweight" rating and set a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Trading Up 1.5 %

Shares of NASDAQ:HOLX traded up $0.85 during mid-day trading on Wednesday, reaching $59.31. 4,497,507 shares of the company were exchanged, compared to its average volume of 1,887,830. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm's 50-day simple moving average is $63.03 and its 200 day simple moving average is $71.87. Hologic, Inc. has a 1 year low of $57.38 and a 1 year high of $84.67. The firm has a market cap of $13.31 billion, a price-to-earnings ratio of 18.71, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.